Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 8;217(2):e20191009. doi: 10.1084/jem.20191009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Tanaka et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Imatinib reduces eT reg cells and augments antitumor immune responses in vitro. (A) In vitro imatinib-dependent induction of tumor antigen–specific CD8⁺ T cells from PBMCs of healthy individuals. PBMCs from HLA-A*0201⁺ healthy individuals (n = 9) were stimulated with Melan-A_26-35 peptide with/without 5 µM imatinib. Reduction of eT reg cells (top) and Melan-A–specific CD8⁺ T cell induction detected by MHC/Melan-A peptide tetramers (bottom). Representative result of three independent experiments. CD4⁺ and CD8⁺ T cells were separately analyzed by FACS. Summary of Melan-A–specific CD8⁺ T cell induction from nine healthy donors (right). (B) In vitro imatinib-dependent induction of tumor antigen–specific CD8⁺ T cells from PBMCs of cancer patients. PBMCs from two HLA-A*0201⁺ and one HLA-Cw*0304⁺ melanoma patients were stimulated with NY-ESO-1_157–165 and NY-ESO-1_92–100 peptides, respectively, with/without 5 µM imatinib (n = 3). Decrease of eT reg cells (top) and increase of NY-ESO-1–specific CD8⁺ T cells detected by MHC/NY-ESO-1 peptide tetramers (bottom). Representative result of three independent experiments. CD4⁺ and CD8⁺ T cells were separately analyzed by FACS. Summary of NY-ESO-1–specific CD8⁺ T cell induction from three melanoma patients (right). Statistical significance was assessed by Student’s two-tailed paired t test in A and B.